Related Experiment Videos
Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement
Insights
Prognostic factors for stage II neuroblastoma in children were analyzed. Regional lymph node involvement was the most significant predictor of survival, indicating a need for better adjuvant treatments for node-positive patients.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Trials
Background:
- Neuroblastoma is a common childhood cancer.
- Stage II neuroblastoma involves localized disease with potential lymph node spread.
- Treatment and prognostic factors for stage II neuroblastoma require further elucidation.
Purpose of the Study:
- To identify prognostic variables in children with stage II neuroblastoma.
- To evaluate the impact of age, tumor characteristics, and treatment on survival.
- To inform future treatment strategies for stage II neuroblastoma.
Main Methods:
- Retrospective review of 33 children diagnosed with stage II neuroblastoma between 1970 and 1977.
- Analysis of patient demographics (age, gender) and tumor characteristics (primary site, lymph node involvement, catecholamine excretion, histology).
- Evaluation of treatment modalities including surgery, radiotherapy, and chemotherapy, alone or in combination.
Main Results:
- Overall 3-year survival rate was 70%.
- Younger age (<1 year) at diagnosis was a favorable prognostic factor.
- Absence of regional lymph node involvement was the most significant predictor of survival; no patients with uninvolved nodes died of neuroblastoma.
- No clear benefit was observed from postoperative radiotherapy or contemporary chemotherapy in this cohort.
Conclusions:
- Regional lymph node status is a critical prognostic indicator for stage II neuroblastoma.
- Subclassification of stage II neuroblastoma into node-positive and node-negative groups is essential.
- Further research into improved adjuvant postsurgical treatments for node-positive patients is warranted.
Abstract:
Thirty-three children aged between 1 month and 16 years (median 1 year, 7 months), were treated for stage II neuroblastoma with surgery, radiotherapy, or chemotherapy, alone or in combination. After 3 years 70% were living, 6 children had died from the disease, and 4 had died as a result of treatment. Patient characteristics (age, gender) and tumour characteristics primary site, presence of lymph node involvement, catecholamine excretion, histology) were reviewed in an attempt to determine prognostic features. While age under 1 year at diagnosis was, as expected, favourable in this series, the most important prognostic variable was the presence or absence of regional lymph node involvement. No patient with uninvolved nodes died of neuroblastoma and the difference in the 3-year survival rate between these patients and those with positive nodes was statistically significant. Although this study of patients treated between 1970 and 1977 provided no clear evidence that either postoperative radiotherapy or contemporary chemotherapy was of benefit, our findings suggest that subclassification of stage II patients into 'node-positive' and 'node-negative' groups will help to define those who might benefit from improved adjuvant postsurgical treatment.